Skip to main content
. 2021 Dec 13;10(12):1983. doi: 10.3390/antiox10121983

Table 4.

Cardiovascular variables (mean ± standard deviation) of oxidative and nitrosative stress of nondiabetic rats (NDR), diabetic control rats (DR), and DR treated with hydroxytyrosol (HT) 5 mg/kg/day p.o. (HT-5), 3′,4′-dihidroxifenilglicol (DHPG) 0.5 or 1 mg/kg/day p.o. (DHPG-0.5, DHPG-1), or their association. n = 10 rats per group.

Variable NDR DR HT-5 DHPG-0.5 DHPG-1 HT-5 + DHPG-0.5 HT-5 + DHPG-1
Imax (ohms) 12.8 ± 2.1 23.1 ± 2.1 (+) 8.8 ± 1.4 (*) 10.7 ± 1.3 (*) 6.9 ± 1.5 (*) 3.0 ± 0.7 (*,a) 3.2 ± 0.7 (*,a)
11-dH-TxB2 (ng/mg urine creatinine) 3.9 ± 0.9 9.7 ± 1.1 (+) 4.4 ± 1.2 (*) 8.9 ± 1.8 6.8 ± 0.9 5.6 ± 1.3 7.8 ± 1.6
6-keto-PGF1α (pg/mg urine creatinine) 14.0 ± 1.4 6.8 ± 1.0 (+) 10.8 ± 1.6 (*) 11.1 ± 0.9 (*) 13.1 ± 1.9 (*) 16.6 ± 1.5 (*,c) 18.7 ± 2.8 (*,c)
MPOx (ng/mL) 0.8 ± 0.08 2.5 ± 0.3 (+) 0.7 ± 0.2 (*) 0.8 ± 0.1 0.8 ± 0.09 0.5 ± 0.1 (*) 0.4 ± 0.08 (*)
VCAM-1 (ng/mL) 4.8 ± 0.8 9.7 ± 0.8 (+) 4.1 ± 0.4 (*) 7.9 ± 0.6 (*) 6.1 ± 0.8 (*) 4.6 ± 0.5 (*) 3.4 ± 0.8 (*,b)

Imax: maximum intensity of platelet aggregation induced with collagen. 6-keto-PGF: 6-keto-prostaglandin F; 11-dH-TxB2: 11-dehydro-tromboxane B2. MPOx: myeloperoxidase. * p < 0.05 with respect to DR. a p < 0.05 with respect to DHPG-0.5; b p < 0.05 with respect to DHPG-0.5, DHPG-1 and HT-5 + DHPG-0.5; c p < 0.05 with respect to HT, DHPG-0.5 and DHPG-1.